Literature DB >> 18645032

Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids.

Margaret E Ackerman1, David Pawlowski, K Dane Wittrup.   

Abstract

Poor tissue penetration is a significant obstacle to the development of successful antibody drugs for immunotherapy of solid tumors, and diverse alterations to the properties of antibody drugs have been made to improve penetration and homogeneity of exposure. However, in addition to properties of the antibody drug, mathematical models of antibody transport predict that the antigen expression level and turnover rate significantly influence penetration. As intrinsic antigen properties are likely to be difficult to modify, they may set inherent limits to penetration. Accordingly, in this study, we assess their contribution by evaluating the distance to which antibodies penetrate spheroids when these antigen properties are systematically varied. Additionally, the penetration profiles of antibodies against carcinoembryonic antigen and A33, two targets of clinical interest, are compared. The results agree well with the quantitative predictions of the model and show that localizing antibody to distal regions of tumors is best achieved by selecting slowly internalized targets that are not expressed above the level necessary for recruiting a toxic dose of therapeutic. Each antibody-bound antigen molecule that is turned over or present in excess incurs a real cost in terms of penetration depth-a limiting factor in the development of effective therapies for treating solid tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18645032      PMCID: PMC2831054          DOI: 10.1158/1535-7163.MCT-08-0067

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  30 in total

1.  Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33.

Authors:  S Welt; C R Divgi; F X Real; S D Yeh; P Garin-Chesa; C L Finstad; J Sakamoto; A Cohen; E R Sigurdson; N Kemeny
Journal:  J Clin Oncol       Date:  1990-11       Impact factor: 44.544

2.  Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors.

Authors:  A Pluen; Y Boucher; S Ramanujan; T D McKee; T Gohongi; E di Tomaso; E B Brown; Y Izumi; R B Campbell; D A Berk; R K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

3.  Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.

Authors:  Vania Kenanova; Tove Olafsen; Desiree M Crow; Gobalakrishnan Sundaresan; Murugesan Subbarayan; Nora H Carter; David N Ikle; Paul J Yazaki; Arion F Chatziioannou; Sanjiv S Gambhir; Lawrence E Williams; John E Shively; David Colcher; Andrew A Raubitschek; Anna M Wu
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

4.  Increasing the serum persistence of an IgG fragment by random mutagenesis.

Authors:  V Ghetie; S Popov; J Borvak; C Radu; D Matesoi; C Medesan; R J Ober; E S Ward
Journal:  Nat Biotechnol       Date:  1997-07       Impact factor: 54.908

5.  Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule.

Authors:  S H Jang; M G Wientjes; J L Au
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

6.  Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules.

Authors:  P A Netti; L M Hamberg; J W Babich; D Kierstead; W Graham; G J Hunter; G L Wolf; A Fischman; Y Boucher; R K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 7.  Pharmacokinetics and biodistribution of genetically-engineered antibodies.

Authors:  D Colcher; G Pavlinkova; G Beresford; B J Booth; A Choudhury; S K Batra
Journal:  Q J Nucl Med       Date:  1998-12

8.  A33 antigen displays persistent surface expression.

Authors:  Margaret E Ackerman; Cecile Chalouni; Michael M Schmidt; Vivek V Raman; Gerd Ritter; Lloyd J Old; Ira Mellman; K Dane Wittrup
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

9.  Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library.

Authors:  R H Begent; M J Verhaar; K A Chester; J L Casey; A J Green; M P Napier; L D Hope-Stone; N Cushen; P A Keep; C J Johnson; R E Hawkins; A J Hilson; L Robson
Journal:  Nat Med       Date:  1996-09       Impact factor: 53.440

10.  Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

Authors:  T Saga; R D Neumann; T Heya; J Sato; S Kinuya; N Le; C H Paik; J N Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

View more
  41 in total

Review 1.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

2.  Concurrent quantification of multiple nanoparticle bound states.

Authors:  Adam M Rauwerdink; John B Weaver
Journal:  Med Phys       Date:  2011-03       Impact factor: 4.071

Review 3.  Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.

Authors:  Shi Xu
Journal:  Pharm Res       Date:  2015-06-25       Impact factor: 4.200

Review 4.  Antibody Drug Conjugates: Preclinical Considerations.

Authors:  Gadi G Bornstein
Journal:  AAPS J       Date:  2015-02-28       Impact factor: 4.009

Review 5.  Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities.

Authors:  Carolyn L Waite; Charles M Roth
Journal:  Crit Rev Biomed Eng       Date:  2012

6.  A mechanistic compartmental model for total antibody uptake in tumors.

Authors:  Greg M Thurber; K Dane Wittrup
Journal:  J Theor Biol       Date:  2012-09-06       Impact factor: 2.691

Review 7.  The development of immunoconjugates for targeted cancer therapy.

Authors:  Brandon G Smaglo; Dalal Aldeghaither; Louis M Weiner
Journal:  Nat Rev Clin Oncol       Date:  2014-09-30       Impact factor: 66.675

8.  Dose dependence of intratumoral perivascular distribution of monoclonal antibodies.

Authors:  John J Rhoden; Karl Dane Wittrup
Journal:  J Pharm Sci       Date:  2011-11-04       Impact factor: 3.534

9.  Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells.

Authors:  Joachim Diessner; Valentin Bruttel; Kathrin Becker; Miriam Pawlik; Roland Stein; Sebastian Häusler; Johannes Dietl; Jörg Wischhusen; Arnd Hönig
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

Review 10.  Affinity and avidity in antibody-based tumor targeting.

Authors:  Stephen I Rudnick; Gregory P Adams
Journal:  Cancer Biother Radiopharm       Date:  2009-04       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.